Patents by Inventor Yasunobu Kurosaki

Yasunobu Kurosaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biaryl derivative
    Patent number: 11932600
    Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the following formula (I): wherein X1 represents a nitrogen atom or CR9, R1 represents a hydrogen atom, a C1-C6 alkyl group, or a C1-C6 alkoxy group, R2 represents a halogen atom, R3 represents a hydrogen atom or a halogen atom, R4 represents a hydrogen atom or a halogen atom, and R5 represents a C1-C3 alkylsulfonyl group, a substituted C1-C6 alkyl group, a substituted C1-C6 haloalkyl group, a substituted C1-C6 alkoxy group, or a substituted C1-C6 alkylamino group, or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: March 19, 2024
    Assignees: Daiichi Sankyo Company Limited, Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Takashi Tsuji, Yasunobu Kurosaki, Koutaro Ishibashi, Anthony B. Pinkerton
  • ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF
    Publication number: 20230121698
    Abstract: Provided herein are small molecule modulators of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 20, 2023
    Inventors: Anthony PINKERTON, Eduard SERGIENKO, Yohei KIYOTSUKA, Katsuji KAGECHIKA, Yasunobu KUROSAKI, Yoshikazu ARAI, Masatoshi NAGAMOCHI, Koutaro ISHIBASHI
  • BIARYL DERIVATIVE
    Publication number: 20210355087
    Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the following formula (I): wherein X1 represents a nitrogen atom or CR9, R1 represents a hydrogen atom, a C1-C6 alkyl group, or a C1-C6 alkoxy group, R2 represents a halogen atom, R3 represents a hydrogen atom or a halogen atom, R4 represents a hydrogen atom or a halogen atom, and R5 represents a C1-C3 alkylsulfonyl group, a substituted C1-C6 alkyl group, a substituted C1-C6 haloalkyl group, a substituted C1-C6 alkoxy group, or a substituted C1-C6 alkylamino group, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: October 22, 2019
    Publication date: November 18, 2021
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Takashi Tsuji, Yasunobu Kurosaki, Koutaro Ishibashi, Anthony B. Pinkerton
  • Sulfonamide compounds
    Patent number: 11046710
    Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: June 29, 2021
    Assignees: Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Shojiro Miyazaki, Masaharu Inui, Yasunobu Kurosaki, Yuko Yamamoto, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Masamichi Kishida
  • Sulfonamide compounds
    Patent number: 11014939
    Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: May 25, 2021
    Assignees: Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Shojiro Miyazaki, Masaharu Inui, Yasunobu Kurosaki, Yuko Yamamoto, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Masamichi Kishida
  • SULFONAMIDE COMPOUNDS
    Publication number: 20200087321
    Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: December 22, 2017
    Publication date: March 19, 2020
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Shojiro Miyazaki, Masaharu Inui, Yasunobu Kurosaki, Yuko Yamamoto, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Masamichi Kishida